文 | 银行螺丝钉 （转载请注明出处） 有偏离自己制定的投资计划。 第二是我们在定投的时候，要综合考虑自 己的心理承受能力和投入的资金量。 定投开始时投入的钱不多，所以心理压 力会小一点。 IEA J V L J F J F J F J F J L L J ▼点击阅读原 文，免费学习大额家庭资产配置课程 而如果遇到下跌的时候感到恐慌，往往 说明这个时候你投的钱可能超出自己的 心理承受能力了。 投的钱越多，心理压力越大。这时候可 能就容易头脑一昏，做出错误的决策。 因此,最好用长期不用的闲钱投资,这笔 钱是遇到下跌你也不慌的金额。 说一个极端的例子，就是这笔钱哪怕打 水漂了，你也不会觉得心疼的那种。 这种程度的资金,做长期投资更容易坚 挂下求。 ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported worldwide sales of $21.9 billion, reflecting a 4.2% increase despite a 470 basis point headwind from Stelara [25][27] - Net earnings for the quarter were $11 billion, with diluted earnings per share at $4.54, significantly up from $1.34 a year ago, primarily due to a $7 billion reversal related to the talc settlement proposal [26][40] - Adjusted net earnings were $6.7 billion, with adjusted diluted earnings per share at $2.77, representing increases of 1.9% and 2.2% respectively compared to Q1 2024 [26][40] Business Line Data and Key Metrics Changes - Innovative Medicine achieved worldwide sales of $13.9 billion, up 4.2%, with U.S. growth at 6.3% and international growth at 1.5% [27][30] - In Oncology, DARZALEX grew by 22.5%, while PERVICTI saw over 100% growth, driven by share gains and capacity expansion [28][30] - MedTech reported worldwide sales of $8 billion, increasing by 4.1%, with U.S. growth at 5.1% and international growth at 3% [32][33] Market Data and Key Metrics Changes - U.S. sales growth was 5.9%, while international sales growth was 2.1% [25] - The company experienced a positive impact of 90 basis points from acquisitions and divestitures on worldwide growth [25] - MedTech performance was affected by one-time events, particularly in orthopedics, which declined by 3.1% [37] Company Strategy and Development Direction - The company plans to invest over $55 billion in the U.S. over the next four years to enhance manufacturing, R&D, and technology [13][15] - The acquisition of Intra Cellular Therapies is expected to bolster the neuroscience portfolio, with CAPLYTA projected to have over $5 billion in peak year sales potential [16][46] - A restructuring program is being implemented to simplify operations in the surgery business, with an estimated cost of $900 million [44][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 guidance despite challenges from Stelara's biosimilars and Part D redesign [7][76] - The company anticipates higher growth in the second half of the year, particularly in MedTech, as new products gain traction [44][51] - Management highlighted the resilience of the diversified business model in navigating headwinds and delivering on financial commitments [57] Other Important Information - The company increased its dividend for the 63rd consecutive year, reflecting its commitment to returning capital to shareholders [17][46] - The effective tax rate for the quarter was 19.3%, influenced by the reversal of the talc settlement accrual [40] Q&A Session Summary Question: Impact of tariffs on guidance - The company discussed $400 million in tariffs primarily affecting MedTech, with limited price leverage to pass costs to customers [58][60] Question: Gross margins in the quarter - Management noted that gross margins were impacted by the loss of Stelara and Part D redesign, with expectations for improvement moving forward [68][70] Question: Erosion of Stelara due to biosimilars - Management indicated that the impact of Stelara's biosimilars was in line with expectations, with overall business growth remaining strong despite this headwind [74][76] Question: Recession impact on business - Management expressed confidence in the healthcare sector's resilience during economic downturns, noting that elective procedures may be delayed but not abandoned [81][84] Question: Section 232 potential pharma tariffs - Management is analyzing the potential impact of Section 232 tariffs, emphasizing the importance of partnering with the administration to mitigate supply chain vulnerabilities [90]

Group 1 - The company held its 37th meeting of the 8th Board of Directors on March 31, 2025, with all 6 participating directors voting [1][2] - The board approved the revision of the internal audit system, with a unanimous vote of 6 in favor [1] - The company approved its investment plan for 2025, totaling 331.3686 million yuan, which includes 288.4672 million yuan for major projects and 42.9014 million yuan for general updates and renovations [1][2] Group 2 - The company authorized the general manager to adjust specific investment projects within the approved investment plan to enhance decision-making efficiency, with a unanimous vote of 6 in favor [2] - The board approved the appointment of Mr. Li Gang as the new Chief Financial Officer, following a nomination and review process, with a unanimous vote of 6 in favor [2] - Mr. Li Gang has a background in accounting and has held various positions in finance, including as the financial head of the company [2]

Group 1 - The company is holding its second extraordinary general meeting of shareholders on March 31, 2025, in Deyang, Sichuan [1][3] - The agenda includes reviewing and voting on several proposals, including compensation for directors and supervisors, and financial agreements with banks [3][4] - The company proposes a total compensation plan for directors and supervisors for the year 2024, which includes basic salary and performance-based salary [2][4] Group 2 - The company plans to apply for a comprehensive credit limit not exceeding RMB 10.14 billion from financial institutions to meet operational funding needs [4][6] - The proposed credit will be used for various financial services, including loans, bill issuance, and financial derivatives [4][5] - The company intends to sign financial service agreements with Agricultural Bank, Bank of China, and other banks to establish long-term cooperative relationships [5][6] Group 3 - The company has outlined its investment plan for 2025, which includes 106 fixed asset investment projects totaling RMB 2.089 billion and 4 equity investment projects totaling RMB 372.9 million [6][7] - The investment plan includes 65 new projects with a total investment of RMB 1.325 billion, and the funding sources include self-funding and bank loans [7]